Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS-7011a in adults with systemic lupus erythematosus and active cutaneous lupus
jRCT2031230588Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE) comparing DS-7011a with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Jun 2024; status: completed.
02
Drugs
DS-7011a
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on jRCT2031230588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230588.